Standard BioTools

Phase A — Understand the business

Lens 1 · Company Overview

Standard BioTools Inc. (Nasdaq: LAB, Delaware, HQ now 50 Milk Street, Boston as of Dec 2025) is — at the reporting level — a multi-omics life-science tools company. Corporate lineage matters here because it is the thesis: Mycometrix (1999) → Fluidigm (2001) → Standard BioTools (Apr 2022). The April 2022 rename coincided with a $250M zero-coupon convertible-preferred infusion from Casdin Capital + Viking Global (conversion $3.40/share) — the moment activist-adjacent life-science investors took control of a struggling Fluidigm and re-cast it as a "set the new standard via strategic consolidation" roll-up platform.

What it actually sells (continuing ops): instrumentation, consumables, and field services across two retained platforms —

• Mass cytometry / spatial proteomics: CyTOF™ and Hyperion™ (single-cell and spatial protein profiling), manufactured in Markham, Canada.
• Microfluidics / genomics: Biomark™ and Integrated Fluidic Circuits ("IFCs"), manufactured in Singapore.

Customers: academic, government, pharma/biotech, and clinical research labs worldwide; end-applications are immuno-oncology, immunology, neurology, infectious disease. Revenue is recurring-ish but not contractual — standard purchase orders, cancellable before shipment, 30–90 day terms; "backlog is not a meaningful indicator of future sales" by the company's own admission. Concentration is moderate: one genomics customer = 12% of revenue (2025); top-5 customers = 26%.

The structural fact that overrides everything: the company has spent 2024–2026 dismantling, not consolidating. It bought SomaLogic (Jan 2024) and Sengenics (Nov 2024) to build a proteomics franchise, then sold the entire SomaScan/aptamer business to Illumina (closed 30 Jan 2026, $350M cash + up to $75M earnout). And on 8 Jun 2026 it agreed to merge the residual into Treeline Biosciences and exit tools altogether. Lens 1's plain-terms answer: this is no longer an operating company you underwrite on its products — it is a recapitalization vehicle with a tools business attached for now.

Lens 2 · Supply Chain

Upstream → company → customer, named where the filing names them:

• Upstream inputs: raw materials for IFCs and reagents are sole/limited-source. The 10-K is explicit: certain metals used in Maxpar reagents are single-sourced; primers for Delta Gene / SNP Type / Access Array assays come from a limited number of sources; "the loss of a single or sole source supplier would require significant time and effort to locate and qualify an alternative source of supply, if at all". The company holds no supply agreements with these metal suppliers and runs minimal inventory — a genuine chokepoint for a sub-scale manufacturer.
• Manufacturing (the company itself): two owned plants — Singapore (IFCs/microfluidics) and Markham, Ontario, Canada (mass-cytometry instruments + Maxpar reagents + genomics reagents).
• Downstream: direct + distributor sales into research labs. Geographic skew is ex-US heavy — 67% of 2025 revenue from outside the US; named single-country concentrations: China 13% ($10.9M), Sweden 10% ($8.6M), US 33% ($28.4M).
• Named exogenous chokepoints the company flags itself: NIH funding pressure (academic-lab demand) and US export controls + tariffs — both called out in the forward-looking-statements risk language, both directly relevant given the China and academic exposure.

This lens passes the "names or it didn't happen" test — but note the supply chain is small. China sales (13%) sitting against US export-control risk is the one supply-chain line that could move numbers.

Lens 3 · Competitive Advantages (moats)

Honest assessment: the moat is thin and shrinking, which is precisely why the company is being recapitalized rather than grown.

• CyTOF / mass cytometry is the one genuinely differentiated franchise — Standard BioTools effectively owns the mass-cytometry niche (metal-tagged single-cell proteomics), a real installed-base + consumables razor/razorblade with switching costs (trained labs, validated panels). This is the asset most likely to fetch a strategic price in the divestiture.
• Microfluidics/IFCs (Biomark) competes in qPCR/genomics against far larger, better-capitalized players (Bio-Rad, Thermo, Bio-Techne, 10x Genomics on the single-cell flank). Here LAB is a price-taker with declining instrument placements (−33% instrument revenue in Q1 2026).
• Bargaining power: weak on both sides. Upstream, sole-source suppliers hold leverage (no contracts). Downstream, customers face low switching costs on the microfluidics side and can defer instrument capex in a constrained-funding environment — which is exactly what happened (consumables −11% in 2025 on "budgetary limitations and constrained funding").
• The tell: a company with a durable moat compounds. This one has shrunk revenue three straight years ($106.3M → $91.0M → $85.3M, 2023→2025) and carries a $1.3B accumulated deficit. The moat is real only for CyTOF, and even there it isn't enough to outrun the cost base. Verdict: niche, not a moat.

Lens 4 · Segments

The company collapsed to a single reportable segment in Q1 2025 ("one operating and reportable segment: the consolidated company") after integrating SomaLogic — so there is no clean proteomics-vs-genomics segment P&L post-2024. What we can break out is revenue by product type and geography (continuing ops) — all:

By product type (FY, $000s):

By geography (FY, $000s): Americas 30,561 / EMEA 35,987 / APAC 18,783 (2025). EMEA is now the largest region and the only one growing — driven by Sweden. Americas fell from $46.2M (2023) to $30.6M (2025), a −34% two-year collapse that tracks the US academic/NIH funding squeeze.

The decelerating cause: consumables (the recurring, high-margin razorblade) declined on customer-budget pressure; services declined because "improved instrument reliability" cut maintenance needs (a perverse signal — your own product quality is deflating your service line). Q1 2026 is the first inflection up: total revenue $21.1M (+5% YoY), consumables +35% to $11.0M, but instruments −33% to $4.5M — a mix shift toward recurring revenue, which is healthier, but off a tiny base and inside a company that's about to be absorbed.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print — Q1 2026, ended 31 Mar 2026)

All figures unless tagged.

• Revenue $21.1M vs $20.2M (+4.6% YoY) — first growth quarter after the multi-year decline.
• Gross profit $11.3M, gross margin 53% (vs 54% PY) — stable, decent for a tools company.
• Loss from operations −$12.5M vs −$27.0M PY — a 54% reduction in operating loss, the headline management wants you to see.
• Net loss from continuing ops −$14.6M (−$0.04/sh) vs −$23.4M (−$0.06) PY.
• Total net loss −$26.0M — but this includes a +$172.3M gain on the SomaScan sale, offset by $39.2M tax expense on that gain, plus the discontinued-ops drag.
• Adjusted EBITDA loss narrowed to −$3.1M from −$14.1M PY — a 78% improvement, "path to positive adjusted EBITDA exiting 2026".
• Guidance: FY2026 revenue $80–85M (roughly flat-to-down vs $85.3M), positive adj EBITDA exit rate.

Balance-sheet flags — the whole story:

• Cash + investments $526.5M at 31 Mar 2026 (vs $213.3M at YE2025), after receiving $363.2M of Illumina consideration and deploying $185.7M into Treasuries.
• Operating cash burn −$46.6M in the quarter — elevated by $12.1M of transaction/restructuring payments + $10.1M of bonus payouts; underlying run-rate burn is lower but still real.
• No debt, no credit facilities — "we have repaid the majority of our traditional debt obligations and no longer maintain access to credit facilities". All-equity balance sheet.
• Accumulated deficit $1,133.5M (down from the 10-K's ~$1.3B because the gain on sale flowed through).
• ~$1B of NOL carryforwards — a meaningful tax shield that is itself part of what makes LAB attractive as a reverse-merger shell.

Market reaction: Q1 print (early May) was received positively — "LAB shares climb on revenue beat and restructuring progress". The stock was ~$1.08 in late May. Then the 8 Jun Treeline announcement crushed it −28%. The market liked the turnaround; it hated the exit.

Full-year 2025 for context (continuing ops, ): Revenue $85.3M (−6%); gross margin 49.9%; SG&A $109.9M = 129% of revenue; R&D $26.0M; restructuring $14.8M; loss from operations −$110.2M; net loss from continuing ops −$58.8M (after a $37.9M tax benefit from a valuation-allowance release tied to the expected Illumina gain); total net loss −$74.9M; operating cash burn −$74.3M.

The single most damning number in the file: SG&A of $109.9M against $85.3M of revenue — corporate overhead that is 129% of the entire top line. This is not a business with a cost problem at the margin; it is a business whose corporate structure costs more than it sells. That is the root cause of why the sponsors chose to recapitalize rather than fix it.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on disk (transcripts=0). From press releases + secondary coverage:

• Tone arc 2024 → 2026: "diversified scaled leader in life-science tools" (SomaLogic close, Jan 2024) → "refocus on core tools after SomaScan sale" (FY2025/10-K, early 2026) → "deploying our capital behind a catalyst-rich oncology pipeline" (Treeline, Jun 2026). The language migrated from operating ambition to capital allocation — management stopped talking about building a tools franchise and started talking about what to do with the cash.
• The recurring phrases: "strategic consolidation," "best-in-class operations," "world-class management team," "annualized cost savings" (>$40M operationalized). The thing they stopped saying is anything about organic tools growth — because there wasn't any.
• Egholm's Treeline-deal quote is the giveaway: "Deploying our capital behind this team and pipeline gives our stockholders exposure to a catalyst-rich portfolio…". A CEO describing his own company as a pool of capital to be redeployed elsewhere is telling you the operating story is over.

Lens 7 · Comps

The only comp math that matters for LAB:

• Headline EV/Sales ≈ 4.9x was cited at the late-May $1.08 price ($426M cap, $86.3M TTM revenue). But that figure ignores the cash. Net of ~$526M cash and ~zero debt, enterprise value is deeply negative — at the $324M June cap, EV ≈ $324M − $526M ≈ −$202M. The market is valuing the entire operating tools business at less than zero and paying ~62 cents on the dollar for the cash.
• Said the cleanest way: price-to-net-cash ≈ 0.62x. The stock trades at a ~38% discount to liquidation cash. That is the comp that defines the situation — not EV/Sales vs Bruker.

Treeline's own mark: the deal values Treeline at $2.5B and Standard BioTools at net cash + $10M ≈ $460M. So the merger itself sets LAB's contribution at ~$460M of value — versus a $324M market price. The ~$136M gap is the trade.

Lens 8 · Stock-Price Catalysts (5-yr pattern of >5% moves)

What actually moves this name:

• Jan 2022 — Casdin/Viking $250M infusion + Fluidigm→Standard BioTools rename (conversion $3.40). Recapitalization event; reset the cap table and the strategy.
• Oct 2023 / Jan 2024 — SomaLogic all-stock merger (1.11x exchange). Received positively relative to the later Treeline deal.
• Jun 2025 — Illumina agrees to buy SomaScan business ($350M + earnout). A value-crystallizing divestiture.
• Jan 2026 — Illumina deal closes, $363M cash in; Q1 2026 print (May) beat → stock up to ~$1.08.
• 20 Apr 2026 — Nasdaq sub-$1 deficiency notice (below $1.00 for 30 consecutive days; cure by 19 Oct 2026).
• 8 Jun 2026 — Treeline reverse-merger announced → −28% in a day.

The pattern is unambiguous: for the last four years, LAB trades on corporate-action news, not on earnings. Every >5% move is a deal — a capital infusion, a merger, a divestiture, a delisting notice, a reverse merger. The microfluidics instrument run-rate is irrelevant to the tape. This is a special-situations / event-driven name, full stop. Underwrite the deal, not the P&L.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO: Michael Egholm, Ph.D. — President & CEO since Jan 2022 (installed with the Casdin/Viking recap), also the CODM. Scientific/operating background. Track record at LAB: a managed decline — revenue −20% over his tenure, a $1.3B accumulated deficit, and ultimately a decision to not run the company organically but to recapitalize it. To be fair, he executed two value-crystallizing transactions cleanly (Illumina sale at a good price; the Treeline deal monetizes the shell + NOLs). His skill set proved to be transactional, not operational — which, for this situation, is what the sponsors needed.
• CFO: Alex Kim. Auditor PwC; ICFR assessed effective; no material weaknesses.
• The real principal: Eli Casdin. Founder/CIO of Casdin Capital, board director, and largest stockholder. Casdin (with Viking Global) controls the company via the 2022 preferred (since converted) — Casdin alone was deemed to beneficially receive ~26.5M shares in the SomaLogic merger and converted Series B-1 preferred into 46.5M common in Mar 2024. This is a Casdin/Viking vehicle. Capital allocation has been their call throughout: build the roll-up (2022), bolt on SomaLogic (2024, also a Casdin position), sell to Illumina (2026), pivot the shell into Treeline (2026).
• Skin in the game: very high at the sponsor level (control block), modest at the operating-management level. Only 227 holders of record — heavily institutional.
• Capital-allocation grade: mixed-to-poor on operations, shrewd on exit. $250M in (2022) + a SomaLogic merger + ~$1.3B cumulative losses produced a tools business worth negative enterprise value. But they avoided the value-trap ending — instead of burning the cash trying to fix an unfixable cost structure, they are handing it to a proven oncology team (Bilenker/Engelman) and taking 16% of a $2.5B-valued biopharma + a CVR on the tools. Read charitably, that is disciplined capital allocation by people who concluded their own operating thesis had failed.
• Archetype: professional-manager CEO operating under an activist-investor control board. For a sub-scale, structurally unprofitable tools company, that combination predictably resolves into financial engineering — which is exactly what happened.

Lens 10 · Forensic Red Flags

Forensic-analyst pass across IS / BS / CF. All unless tagged.

• Cash vs earnings divergence: clean and in the conservative direction — the company is cash-rich and loss-making, not the dangerous reverse. The −$26.0M Q1 net loss includes a non-cash-distorting +$172.3M gain on sale; underlying operating cash burn (−$46.6M) is worse than reported net loss, but explainable (transaction + bonus + restructuring payouts). No revenue-recognition aggression evident; product revenue at point-of-shipment, services straight-line — vanilla.
• Goodwill: $111.9M of goodwill — the entire balance — was allocated to the SomaScan disposal group and derecognized at the Illumina close. So continuing ops carry zero goodwill — no impairment overhang left. Notably, no goodwill was ever impaired despite the proteomics business being sold at a value that triggered a $172M gain — the bargain-purchase accounting (the 2024 SomaLogic merger booked a $25.2M bargain purchase gain because LAB's stock fell between announcement and close) means the assets came on cheap.
• SBC flattering non-GAAP: real but disclosed — SG&A rose partly on +$5.5M additional stock-based comp from option grants in 2025, and $4.1M of accelerated SBC hit Q1 2026 on the SomaScan-employee RSU acceleration. The adj-EBITDA bridge leans on SBC add-backs as every tools company's does; watch the gap when underwriting the "positive adj EBITDA exit" claim.
• Tax / valuation allowance: the FY2025 $37.9M income-tax benefit came from a partial release of the US deferred-tax valuation allowance, justified by "the expected gain on the sale of the SomaScan Business". Legitimate, but it means the 2025 net-loss improvement is partly a tax artifact tied to a one-time event, not operating progress. The ~$1B NOL is the residual asset.
• Related-party flag (the one genuine yellow flag): in Dec 2025 the company invested $5.0M in convertible notes of a private life-sciences company "alongside a fund associated with Mr. Casdin" — the controlling shareholder. Small ($5M) and disclosed, but it is a related-party co-investment of corporate cash next to the board's principal. In a company about to distribute ~$450M of that cash into a deal, related-party uses of the treasury deserve scrutiny.
• Restructuring as a recurring line: restructuring/severance has run every year ($14.8M in 2025, $12.5M in 2024; ~20% of the global workforce cut) — chronic, consistent with a perpetual-reorganization story.

Regulatory findings (required):

• SEC Litigation Releases / AAERs: None. Verified via SEC EDGAR EFTS (LR + AAER) for "Standard BioTools," 2021-06-21 → 2026-06-21.
• 10-K Item 3 (Legal Proceedings): the company directs to the financial-statement notes; no material litigation disclosed — ordinary-course only.
• Non-SEC (FTC/DOJ/FDA/etc.): web search surfaced no material enforcement actions, consent decrees, fines, or penalties against Standard BioTools. The Illumina transaction itself is a closed, completed M&A — not an enforcement matter.
• The one live regulatory item is a listing matter, not an enforcement matter: Nasdaq minimum-bid-price deficiency (notice 20 Apr 2026; cure deadline 19 Oct 2026). A reverse stock split at the Treeline close is the contemplated cure.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-21. Clean compliance record; the only overhang is the sub-$1 listing rule.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

An EPS projection on the legacy tools business is the wrong model — by H2 2026 the entity is expected to be Treeline (TRLN), a pre-revenue clinical-stage oncology company, and LAB common converts into ~16% of it + a CVR. So I frame this as a deal-outcome valuation, not a 3-year EPS build, and log the scoreable forecast on the binary that actually resolves (does the Treeline merger close) rather than on an EPS line that won't exist.

Two regimes:

A) Deal closes (base case, H2 2026) — value = your 16% of TRLN + CVR.

• Pro-forma combined cash >$900M, runway into 2029.
• Treeline marked at $2.5B equity value in the deal.
• LAB holders own ~16% → implied stake value ≈ $2.5B × 16% ≈ $400M, plus the CVR on mass-cytometry + microfluidics divestiture proceeds + up to $50M Illumina earnout.
• Against a ~$324M market cap today, the deal-mark value (~$400M + CVR) implies ~25%+ upside if you accept Treeline's $2.5B private mark holds in the public market. That "if" is the entire risk — private oncology marks routinely de-rate on listing.

B) Deal breaks → LAB reverts to a cash shell. Floor ≈ net cash ≈ $1.10–$1.35/share. At $0.83 today, the downside-to-cash is itself positive — you are buying below liquidation value. But a broken deal also means resuming a −$74M/yr operating burn on an unwanted tools business, so the cash erodes; the realistic break floor is high-$0.90s to ~$1.20, still at or above today's price.

The asymmetry: downside ≈ today's price (cash floor), upside ≈ Treeline pipeline re-rate. That is a structurally favorable skew for an event trader — but it is a bet on a specific oncology pipeline's public-market reception and clinical readouts, not on a tools business.

Scoreable forecast to log (Lens 11 contract): "LAB/Treeline merger closes (S-4 effective + LAB shareholder approval) by 2026-12-31." Suggested p ≈ 0.80 — Treeline stockholders have already approved, both boards approved, financing is the cash already on LAB's balance sheet, and Casdin/Viking control the LAB vote. Primary break risk is a superior proposal for the cash or a shareholder/ISS revolt over the 16%/84% split. (Per --watchlist rules, forecast.ts create is skipped in the sweep; logging the binary above is the recommendation for a conviction pass.)

Lens 12 · Bull vs Bear

Bull case. LAB is a sub-NAV cash box being converted into a high-pedigree oncology bet at a discount. You buy at ~$0.83 / ~$324M cap; the deal values your contribution at ~$460M net cash + $10M, and hands you ~16% of a $2.5B Treeline run by Josh Bilenker (built Loxo, sold to Lilly for $8B) and Jeff Engelman (ex-Novartis oncology head) — a team with a literal $8B prior outcome. Treeline brings ~$1.2B raised, a pan-KRAS inhibitor (TLN-372), a BCL6 degrader (TLN-121), and an EZH2 inhibitor (TLN-254), all in Phase 1, plus combined >$900M cash to 2029 — fully funded through multiple readouts. You also keep a CVR on the CyTOF/microfluidics sale + $50M Illumina earnout — free optionality on the legacy assets. The pre-merger downside is a cash floor at/above the current price. This is the rare setup where the floor is the entry price and the ceiling is an oncology platform.

Bear case (2–3 permanent-impairment risks).

1. You're paying for a private mark that may not survive listing. Treeline's $2.5B is a venture mark from ARCH/OrbiMed/GV/KKR-type rounds; clinical-stage oncology with three Phase 1 assets and no pivotal data routinely lists 30–60% below its last private round in 2026's biotech tape. Your "~25% upside to the deal mark" can become −40% to public reality. The −28% drop on announcement is the market front-running exactly this.
2. Dilution + loss of control. LAB holders are diluted to 16% and get 2 of 12 board seats. You are a passenger on someone else's pipeline; the people who raised the cash (Casdin/Viking) chose to exit operating control — that's a vote of no-confidence in the legacy business you'd otherwise be buying cheap.
3. The CVR is soft. Mass cytometry + microfluidics must be sold to monetize; "Treeline does not intend to operate" them and the company is merely "exploring options including divestitures" with open-ended timelines. A negative-enterprise-value tools business is hard to sell well; the CVR could pay little. (Some coverage even flags a wind-down obligation for unsold portions if no deal by S-4 effectiveness — i.e., the assets could be liquidated, not sold.)

Pre-mortem (18 months out, thesis broke): The merger closed; TRLN listed and promptly de-rated to ~$1.5B as the biotech window stayed shut; a TLN-372 (KRAS) Phase 1 update disappointed on durability vs. entrenched Krazati/adagrasib; LAB-legacy holders' 16% is now worth less than the cash that went in; the mass-cytometry divestiture fetched a fire-sale price and the CVR paid pennies. Net: you converted a 0.62x-of-cash bargain into a clinical-stage equity that fell faster than the cash you gave up.

Are multiples too high? Not on LAB itself (it trades below cash). The stretched mark is Treeline's $2.5B private valuation — that's the number to interrogate, and it's the one you inherit.

Contrarian view (what the market refuses to see): The −28% reaction treated this as "tools investors getting diluted into biotech they didn't sign up for." The contrarian read is that the −28% over-punished the cash-floor protection — LAB still trades below net cash with a free Treeline call option and a free CVR. The market priced the dilution and ignored that your downside is bounded by ~$520M of Treasuries. For an event-driven book (not a buy-and-hold tools thesis), the post-drop price is more interesting than the pre-drop price.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• What structurally breaks the money machine? It already broke — the tools business earns negative enterprise value and the operators gave up on it. There is no operating engine to underwrite; you're underwriting a venture-mark and a management team's next pipeline. "Buy below cash" is only a floor if the cash stays — and ~$450M of it is contractually leaving the building into Treeline's burn (>$900M combined, gone by ~2029).
• Where's the revenue concentration risk? Irrelevant to the trade now — but note China 13% + Sweden 10% + one customer 12% means the residual tools business (the CVR collateral) is concentrated and export-control-exposed, making a clean high-value divestiture harder.
• Most dangerous competitor bulls underestimate: for the CVR's CyTOF asset, the entire spatial-biology field (10x Genomics, Akoya, Bruker/NanoString IP) has moved past metal-tag mass cytometry toward imaging/sequencing-based spatial — the franchise bulls think is "differentiated" may be a declining modality, depressing divestiture value.
• Worst capital-allocation moves: $250M in (2022) + a dilutive SomaLogic merger (2024) → ~$1.3B cumulative losses → a tools business worth less than zero. The related-party $5M convertible-note co-invest alongside Casdin's fund is a small but real governance smell on a company with a controlling shareholder now steering ~$450M of cash into a deal.
• What must hold for today's price? That the merger closes (≈80%) AND Treeline's public mark approximates its private $2.5B (much less certain). If growth/data disappoints 20–30%, TRLN re-rates well below the implied 16% stake value, and the "discount to cash" you bought evaporates because the cash is now Treeline's, not yours.
• Single permanent-impairment scenario, and plausibility: TRLN lists, the 2026–27 biotech window stays shut, the lead KRAS/BCL6 Phase 1 reads out mixed, and the stock settles 40–50% below the deal mark — entirely plausible given the base rate for clinical-stage oncology de-SPAC-style listings. The CVR pays little because the tools assets get liquidated. Plausibility: moderate-to-high — this is the modal bear outcome, not a tail.

Lens 14 · Management Questions (15, ordered by information value)

1. What is the explicit net-cash adjustment mechanism — at what closing-cash level does the 16%/84% split move, and what is the floor below which LAB holders can walk?
2. What is the expected near-term burn at Treeline, and does ">$900M to 2029" assume the current three Phase 1 programs only, or pipeline expansion through 2028?
3. For the mass-cytometry + microfluidics divestiture: is there a signed LOI or active process today, an expected value range, and a hard deadline / wind-down trigger if unsold by S-4 effectiveness?
4. How is the CVR valued and structured — what proceeds thresholds pay out, in cash or TRLN shares, and what's the realistic estimate for mass-cytometry sale value given the modality's competitive position?
5. Why a reverse merger into Treeline rather than returning the ~$450M net cash to LAB holders directly (a tender at/above net cash), given LAB trades below cash?
6. Did the board run a competitive process for the cash shell + ~$1B NOLs, or was Treeline a bilateral negotiation driven by Casdin/Viking's existing relationships?
7. What synergy or use justifies Treeline taking a public listing via LAB now versus a conventional IPO — is this fundamentally an IPO-window workaround?
8. How much of the ~$1B NOL survives the ownership change under Section 382 limitations post-merger, and what is the usable annual amount?
9. On the related-party $5M convertible note co-invested alongside Mr. Casdin's fund — what governance process approved deploying corporate cash next to the controlling shareholder, and are there other such positions?
10. What is TLN-372 (pan-KRAS)'s differentiation versus approved/advanced KRAS agents (adagrasib/sotorasib and pan-KRAS rivals), and when is the next clinical readout?
11. What are the 2026/2027 catalyst dates for TLN-121 (BCL6) and TLN-254 (EZH2), and which is the value-driver?
12. What insider/sponsor ownership (Casdin, Viking, ARCH, OrbiMed, GV, KKR) results in the combined TRLN, and are there lock-ups?
13. What is the plan to cure the Nasdaq sub-$1 bid deficiency — confirmed reverse split ratio and timing relative to the 19 Oct 2026 deadline?
14. What were the all-in transaction + restructuring cash costs in 2025–26, and what's the clean go-forward corporate cost base after the ~$40M annualized savings?
15. If the merger does not close, what is the board's committed plan for the ~$520M cash — return it, or another acquisition?

---